Search alternatives:
ppm decrease » _ decrease (Expand Search), nn decrease (Expand Search), pa decreased (Expand Search)
ns decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 ng » 50 mg (Expand Search), 10 ng (Expand Search), 5 ng (Expand Search)
ppm decrease » _ decrease (Expand Search), nn decrease (Expand Search), pa decreased (Expand Search)
ns decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 ng » 50 mg (Expand Search), 10 ng (Expand Search), 5 ng (Expand Search)
-
161
-
162
-
163
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
Published 2022“…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
-
164
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
Published 2022“…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
-
165
FTY720 decreased viability, proliferation, and motility and induced apoptosis in human hepatoblastoma cells.
Published 2019“…<p>(A) Following 24 hours of treatment with FTY720, the viability of HuH6 cells measured using the alamarBlue cell viability assay was significantly decreased (LD<sub>50</sub> = 8.4 μM, p ≤ 0.05). …”
-
166
-
167
Predicting pattern diversity decreases as a function of and .
Published 2025“…(a) and (b): Average negative predictive value for and , respectively for and . …”
-
168
S3 File -
Published 2023“…At higher concentrations some desorption was observed (36% at 50 ppm) but was reduced at lower concentrations (1–3% at < 5 ppm). …”
-
169
S1 File -
Published 2023“…At higher concentrations some desorption was observed (36% at 50 ppm) but was reduced at lower concentrations (1–3% at < 5 ppm). …”
-
170
Key properties of MCPA.
Published 2023“…At higher concentrations some desorption was observed (36% at 50 ppm) but was reduced at lower concentrations (1–3% at < 5 ppm). …”
-
171
S2 File -
Published 2023“…At higher concentrations some desorption was observed (36% at 50 ppm) but was reduced at lower concentrations (1–3% at < 5 ppm). …”
-
172
-
173
-
174
-
175
<i>Bbs1</i><sup><i>M390R/M390R</i></sup> mice have decreased hippocampal proliferation.
Published 2021“…The Red Bar line represents 50μm. G.) Decreased proliferation in the dentate gyrus of P3 <i>Bbs1</i><sup><i>M390R/M390R</i></sup> mice. …”
-
176
-
177
-
178
-
179
-
180